Vitrolife Stock Price, News & Analysis

Vitrolife AB reported strong financial performance for the first quarter of 2023. Sales reached SEK 854 million, marking a 14% increase, with local currency growth of 9% excluding discontinued operations. Consumables sales rose by 12%, Technologies by 7%, and Genetic Services by 7% as well. All regions showed growth: APAC 23%, Americas 6%, and EMEA 1%. The gross margin improved to 56.8%, while EBITDA was SEK 262 million, reflecting a margin of 33.0%. Net income increased to SEK 99 million, resulting in SEK 0.74 per share, up 23%. Following the reporting period, Jón Sigurdsson became interim CEO, with new CEO Bronwyn Brophy set to join on August 1, 2023.

Vitrolife AB is scheduled to hold a conference call on April 21, 2023, at 10:00 a.m. CET, to discuss its interim report for Q1 2023. The call will be conducted in English, and registration is required to participate. During the call, key executives, including Jón Sigurdsson, Interim CEO, and Patrik Tolf, CFO, will be present. The interim report will be released at 8:00 CET on the same day, and presentation materials will be available on the company website prior to the call. A recorded version of the call will be accessible for seven days post-event.

Vitrolife AB invites shareholders to its Annual General Meeting on April 27, 2023, at 4:00 PM in Gothenburg, Sweden. Shareholders must notify attendance by April 21, 2023, and be recorded in the share register by April 19, 2023. Key proposals include a dividend of SEK 0.85 per share, re-election of the Board members, and authorization for the Board to issue new shares. The total remuneration proposed for Board members is SEK 3,600,000, unchanged from last year. Other agenda items include amendments to facilitate postal voting and acquisition of the company's own shares.

Vitrolife AB reported strong financial results for Q4 and the full year 2022. Sales surged to SEK 855 million, a 66% increase driven by organic growth of 11%, acquired growth of 37%, and a currency effect of 18%. EBITDA reached SEK 273 million with a margin of 31.9%. For the full year, sales totaled SEK 3,234 million, up 92%, with EBITDA improving to SEK 1,050 million. The company announced the appointment of Bronwyn Brophy as new CEO starting August 2023, with an interim CEO from April 2023. Additionally, a proposed dividend of SEK 0.85 per share was announced.

Bronwyn Brophy has been appointed as the new CEO of Vitrolife (OTC-PINK:VTRLY), starting August 1, 2023. Brophy brings substantial leadership experience from previous roles at Thermo Fisher Scientific, Medtronic, and Johnson & Johnson. She will replace Thomas Axelsson, who will step down on March 31, 2023, with Jón Sigurdsson serving as interim CEO until Brophy's arrival. The board expects Brophy's experience will drive growth and enhance shareholder value. Sigurdsson praised her international experience as vital for the company’s future.

Vitrolife AB (OTC-PINK:VTRLY) has announced a conference call scheduled for February 2, 2023, at 10:00 a.m. CET, to present its Year-end report for 2022. Participants include CEO Thomas Axelsson and CFO Patrik Tolf. The press release for the report will be available at 8:00 a.m. CET on the same day. Interested parties can register for the call via a provided link, which will give access to necessary dial-in information. A recorded version of the call will be accessible for seven days post-event. For additional information, presentation materials will be available on the company's investor webpage.

Vitrolife's CEO Thomas Axelsson has acquired 12,000 shares valued at 2,124,000 SEK, increasing his total holdings to 25,000 shares. This significant purchase reflects confidence in the company's future performance. The transaction will comply with regulations outlined by the Swedish Financial Supervisory Authority and was disclosed on October 28, 2022. The information is part of Vitrolife's obligations under the EU Market Abuse Regulation.